http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Biobehavioral Health Research: A nursing study of women with and without fibromyalgia
Landis, Carol A.,Lentz, Martha J. The Research Institute of Nursing Science Seoul Na 2005 간호학의 지평 Vol.2 No.1
Biobehavioral nursing research is focused on generating knowledge that examines relations among biological, behavioral, and social dimensions of health to improve outcomes. In this paper we review the findings of a biobehavioral nursing study of individuals with fibromyalgia (FM) that was framed from the perspective of an individual human response model, the FM literature, and our previous studies in midlife women. We were particularly interested in the studying the role of 'arousal' secondary to pain or to dysregulated hypothalamic-pituitary-adrenal (HPA) axis hormones during sleep and the impact on symptom expression. Unexpectedly, we did not find evidence of, arousal' or abnormal amounts of HPA axis hormones but we did find reduced amounts of growth hormone (GH) and prolactin (PRL) and of sleep spindle activity, a biomarker of sleep maintenance. We discuss these new findings and how our thinking was re-shaped to better understand the role that disturbed sleep plays in symptom expression in FM. It is argued that disturbed sleep maintenance mechanisms coupled with dysregulated somatotrophic-growth hormone axis and sleep-related PRL render individuals vulnerable to the development of or exacerbations of FM symptoms.
William T. Bianco,Robert Landis 한국외국어대학교 국제지역연구센터 2016 International Area Studies Review Vol.19 No.3
The 1990s agreements that created the International Space Station (ISS) described the effort as a partnership of equals, a joint venture between organizations that remained independent in terms of many procedures, norms, goals, and the assumptions underlying these factors. As a result, successful joint ISS operations required the participants, most notably the American and Russian space programs, to reconcile different procedures, norms, and training regimes, as well as the beliefs that underlie these practices. Drawing on a combination of operational experience, firsthand observation, and interviews, this paper focuses on how the two programs reduced conflict and engendered cooperation. It also uses the ISS experience to consider how future joint efforts can be designed to minimize conflict between international partners.
Kim, Young-Kwan,Landis, Ryan,Vachet, Richard W.,Rotello, Vincent M. American Chemical Society 2018 ACS APPLIED MATERIALS & INTERFACES Vol.10 No.42
<P>Self-oxidative copolymerization of dopamine with α-cyano-4-hydroxycinnamic acid (CHCA) provides an efficient and multifunctional platform for laser desorption/ionization time-of-flight mass spectrometry (LDI-TOF-MS) analysis. The polydopamine coating layer embedded with the CHCA matrix can be readily formed on nanomaterials and solid substrates without additional surface treatments to generate an efficient LDI-TOF-MS platform for the analysis of small molecules as well as synthetic polymers. This coating can be further functionalized with specific ligands for target enrichment from complex biological media, providing analyte capture for subsequent LDI-TOF-MS analysis.</P> [FIG OMISSION]</BR>
( Eric Lawitz ),( Charles S. Landis ),( Benedict J. Maliakkal ),( Maurizio Bonacini ),( Grisell Ortiz-lasanta ),( Jin Youn ),( Jie Zhang ),( Erik Mogalian ),( Shampa De-oertel ),( Anu O. Osinusi ),( D 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: Despite higher concentrations of sofosbuvir (SOF) metabolite, GS-331007, in patients with severe renal impairment (RI), retrospective case series and claims database analyses have suggested substantial use of ledipasvir (LDV)/SOF in this population with no untoward effects described. The current study evaluated the safety, efficacy, and pharmacokinetics (PK) of LDV/SOF (90/400 mg) once-daily for 12 weeks in patients with genotype (GT) 1 HCV-infection and severe RI. Methods: Treatment naïve or experienced patients with or without compensated cirrhosis and creatinine clearance (CLcr) = 30 mL/min (Cockcroft-Gault equation), not on dialysis, received open-label treatment with LDV/SOF once daily for 12 weeks. Virologic response, pharmacokinetics (PK), and safety, including echocardiograms, were assessed. Results: Of the 18 patients enrolled and treated, mean (range) CLcr at baseline was 24.9 (9.0-39.6) mL/min. All had GT1 HCV infection (14 GT1a and 4 GT1b), 14 (78%) were treatment naïve, and 2 (11%) had cirrhosis. All patients completed 12 weeks of LDV/SOF treatment. There were no early discontinuations nor any on-treatment virologic failures. The SVR12 rate is 100% (18/18). Plasma concentrations of the terminal SOF metabolite GS-3310007 were approximately 6 fold higher than in the LDV/SOF Phase 3 trials. SOF and LDV concentrations were similar to those observed in patients with normal, mild or moderate RI. The most common adverse events (AEs) were fatigue (22%), headache (22%), and hyperkalemia (17%). Six serious AEs were reported among 4 patients (22%), including 2 renal events; no SAEs were considered related to study drugs. There were no treatment-related cardiac AEs, including bradycardia, and no meaningful changes in QTc intervals or other parameters. Conclusions: Treatment with LDV/SOF (90/400 mg) for 12 weeks in genotype 1 patients with and without cirrhosis and severe renal impairment resulted in 100% SVR12 rate. The regimen was safe and well-tolerated with no treatment discontinuations and no treatment-related SAEs.